Open access · OA
via OpenAlex
Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics
Girish Harinath, Sajad Zalzala, Andy Nyquist, Maartje C.A. Wouters, Anar Isman, Brandon Verkennes
· 2024 · ▲ 1 citations
Abstract
Low-dose naltrexone (LDN) has been suggested to target the multiple telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition) and improve healthspan(definition) metrics in humans.However, to date, no studies have evaluated LDNs potential as a gerotherapeutic.We collected real-world data utilizing the short form 36 quality of life (QoL) assay, immune status questionnaire, and a patient-reported health assessment to evaluate the effectiveness of LDN for improving multiple healthspan metrics in a normative aging cohort still within their healthspan.Most participants taking LDN for ≥3 months (69.2%) had a significant improvement in mean QoL scores (29.9%).The largest improvements were observed in the QoL categories of energy and fatigue, physical role limitations, emotional role limitations, social functioning, and pain.Participants also exhibited a significant improvement in mean immune function (24.6%).Data from a patient-reported health assessment at ≥4 weeks (N = 5500) and ≥10 weeks (N = 1450) of LDN use revealed that a majority of participants reported improvements in pain, fatigue, inflammation, and mood.A healthspan-enhancing drug should demonstrate the ability to enhance the health of individuals before significant age-related diseases and disability arise, thereby extending the period of life spent in good health.We found that 45% of responders to LDN had average to above-average baseline QoL scores, which increased to 76.6% of responders after LDN treatment.Furthermore, 23.8% of individuals taking LDN were able to discontinue other medications and 10.5% of participants reported avoiding planned clinical procedures.These data suggest that LDN might play a role in enhancing healthspan, warranting further research into its potential geroprotective effects.AgingBio, 2, e20240032,
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.59368/agingbio.20240032
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Harinath, G., Zalzala, S., Nyquist, A., Wouters, M.C., Isman, A., & Verkennes, B. (2024). Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics. https://doi.org/10.59368/agingbio.20240032
Vancouver
Harinath G, Zalzala S, Nyquist A, Wouters MC, Isman A, Verkennes B. Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics. 2024. doi:10.59368/agingbio.20240032.
BibTeX
@article{girish2024LowDos,
title = {Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics},
author = {Girish Harinath and Sajad Zalzala and Andy Nyquist and Maartje C.A. Wouters and Anar Isman and Brandon Verkennes},
year = {2024},
doi = {10.59368/agingbio.20240032},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Antioxidants 2024
Open access · CC-BY
Spermidine Enhances Mitochondrial Bioenergetics in Young and Aged Human-Induced Pluripotent Stem Cell-Derived Neurons
Centre Hospitalier Universitaire de Saint Etienne 2021
Open access · US-GOV
Effects of Mode of Contraction on Neuromuscular Fatigue in Young People Aged 18 to 35, Aged 60 to 80 and Very Old People Aged Over 80
Aging Cell 2008
Open access · OA
Valproic acid extends<i>Caenorhabditis elegans</i>lifespan
International Journal of Science and Research (IJSR) 2024
Open access · CC-BY
Evaluating the Impact of Anti-Aging Integrative Therapy on Cellular Aging and Quality of Life
iScience 2024
Open access · CC-BY
Low-dose naltrexone extends healthspan and lifespan in C. elegans via SKN-1 activation
AgelessRx 2022
Open access · US-GOV